Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Colorectal adenocarcinoma, Wild KRAS, 18-75 yr~* Estimated life expectancy of more than 3 months~* ECOG performance status of 0 to 1 at study entry~* Adequate bone marrow function~* Adequate liver function~* Documented progression during or within 3 months of irinotecan-containing regimens as a first-line chemotherapy~* Immunohistochemical evidence of a presence or absence of EGFR expression by PharmDx Kit~* Informed Consent~Exclusion Criteria:~* Central nervous system (CNS) metastases or prior radiation for CNS metastases.~* Intestinal obstruction or impending intestinal obstruction due to peritoneal carcinomatosis~* Surgery (excluding biopsy for diagnosis) during 4 weeks prior to inclusion in the study.~* Evidence of gastrointestinal bleeding~* Exposure to Cetuximab~* Prior administration of monoclonal antibodies, EGFR signal transduction inhibitors or EGFR-targeted treatment~* KRAS mutant Status~* Patients with serious toxicity to previous irinotecan-based chemotherapy~* Other serious illness or medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EGFR expression (Type: EXPERIMENTAL): Patients' accrual will be adjusted by EGFR expression (positive vs. negative)

Based on this trial design, predict the completion outcome and termination type (if applicable).